WHO ICTRP trial
Efficacy and safety of once daily versus twice daily xuezhikang, a red yeast…
ChiCTR-IIR-17013660 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-IIR-17013660 |
|---|---|
| Public title | Efficacy and safety of once daily versus twice daily xuezhikang, a red yeast rice, in patients with hypercholesterolemia: a multicenter randomized, open-label, noninferiority trial |
| Scientific title | Efficacy and safety of once daily versus twice daily xuezhikang, a red yeast rice, in patients with hypercholesterolemia: a multicenter randomized, open-label, noninferiority trial |
| Primary sponsor | The First Affiliated Hospital, Sun Yat-Sen University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | hypercholesterolemia |
| Interventions | experimental group:Xuezhikang 1200mg orally once daily;control group:Xuezhikang 600mg orally twice daily |
| Registration date | Dec 3, 2017 |
| Target size | experimental group:158;control group:158 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: